Physician profile
Michael A Moore
NPI 1205815214
$3,520.06
in general payments reported to CMS, 2019-2025
28 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $308 · 2021: $638 · 2022: $463 · 2023: $251 · 2024: $440 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $800.54 | 2019-2025 | |
| Novo Nordisk INC | $731.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $607.26 | 2019-2025 | |
| Amgen INC. | $227.16 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Glaxosmithkline, LLC. | $225.48 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $220.97 | 2019-2022 | |
| Dexcom, INC. | $197.21 | 2022-2025 | Dexcom G6 Transmitter |
| Insmed, INC. | $59.45 | 2025 | Brinsupri, Arikayce |
| Merck Sharp & Dohme LLC | $43.67 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Phathom Pharmaceuticals, INC. | $42.64 | 2024 | Voquezna |
| Verona Pharma, INC. | $34.01 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $33.45 | 2019-2020 | |
| Lilly USA, LLC | $27.78 | 2022-2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.18 | 2019 | |
| Boston Scientific Corporation | $21.92 | 2025 | General - Pain Management |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $20.87 | 2021 | |
| Abbott Laboratories | $20.23 | 2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $19.60 | 2020 | |
| Abbvie INC. | $19.21 | 2021 | |
| Axsome Therapeutics, INC. | $18.04 | 2025 | Auvelity |
| Exact Sciences Corporation | $17.97 | 2025 | Cologuard Collection Kit |
| Viatris Specialty LLC | $17.88 | 2025 | Yupelri |
| Shire North American Group INC | $16.98 | 2019 | |
| Mylan Specialty L.P. | $16.67 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.48 | 2025 | Relistor |
| Arbor Pharmaceuticals, INC. | $15.16 | 2020 | |
| Gilead Sciences, INC. | $13.06 | 2021 | |
| Allergan, INC. | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.